LG Chemical has officially developed a new type of cancer treatment drug.

On April 1st, LG Chem announced a strategic partnership agreement with the American company Frontier Medicines to initiate Phase I clinical trials for the anti-cancer drug candidate "FMC-220". LG Chem will receive global exclusive rights for research and commercialization. Through this partnership, LG Chem will be responsible for global market development and commercialization, excluding China, and will make upfront payments to Frontier Medicines, followed by staged payments for research and commercialization expenses and sales royalties.